Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A...

Area of Science:

• Oncology
• Translational Research
• Biomarkers

Background:

• Circulating tumor cells (CTCs) are established prognostic markers in metastatic breast cancer (MBC).
• Hormone receptor-positive (HR+)/HER2-negative MBC patients progressing on CDK4/6 inhibitors face limited treatment options.
• Understanding CTCs' role in advanced disease is crucial for optimizing therapy.

Purpose of the Study:

• To evaluate the prognostic significance of baseline circulating tumor cells (CTCs) in HR+/HER2- MBC patients.
• To assess the interaction between CTC levels and different treatment regimens (fulvestrant alone vs. combinations) in patients progressing on CDK4/6 inhibitors.
• To determine if CTC enumeration can guide treatment selection in this patient population.

Main Methods:

• Phase II, multicenter, randomized PACE trial involving HR+/HER2- MBC patients post-aromatase inhibitor and CDK4/6 inhibitor progression.
• Patients randomized to fulvestrant (F), F+palbociclib (F+P), or F+P+avelumab (F+P+A).
• Baseline CTCs enumerated; patients classified as StageIV indolent (<5 CTCs) or StageIV aggressive (≥5 CTCs). Progression-free survival (PFS) was the primary endpoint.

Main Results:

• Among 203 evaluable patients, 76% had detectable CTCs, with 49% classified as StageIV aggressive.
• Baseline CTCs were prognostic: median PFS was 5.7 months for StageIV indolent vs. 3.5 months for StageIV aggressive (HR 1.69).
• StageIV aggressive patients showed improved PFS with F+P (HR 0.43) and F+P+A (HR 0.26) versus F alone; no benefit observed in StageIV indolent patients.

Conclusions:

• Baseline CTC enumeration is a significant prognostic factor in HR+/HER2- MBC.
• StageIV aggressive patients derive superior benefit from combination therapies (F+P or F+P+A) compared to fulvestrant alone.
• CTC levels may aid in tailoring treatment strategies for advanced breast cancer patients.